ArticleFrontiers in oncology2026
Genomic analysis in chemotherapy-naïve prostate cancer prior to PSMA-targeted treatment.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [BMC cancer · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chemotherapy is typically administered prior to consideration of tandem [ Methods: Blood samples were obtained from mCRPC patients receiving [ Results: This case series included five chemotherapy-naïve patients-four with baseline characterization and one with longitudinal follow-up-providing a rare window into cfDNA CNAs at treatment initiation. Recurrent alterations included amplifications in chromosomes 1q, 7q, and 8q, and losses in 8p. Additional events such as 12q amplification and partial 9q gain were also observed. In Patient 5, serial cfDNA analysis demonstrated stable 8p loss and 8q gain across multiple treatment cycles, despite clinical progression, suggesting clonally persistent genomic drivers. Discussion: Baseline cfDNA CNA profiling in chemotherapy-naïve mCRPC reveals recurrent chromosomal imbalances-particularly 8p loss and 8q gain-that may represent intrinsic, stable features of advanced disease. These findings highlight the exploratory potential of cfDNA-based genomics in rare PSMA-RPT cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.